Adafosbuvir

• Description:

  Adafosbuvir (AL-335), a precursor compound of a uridine-based nucleotide analog polymerase (NS5B) inhibitor, has potent antiviral activity against HCV and acts as a potent inhibitor of HCV RNA polymerase[1].

• Product Name Alternative:

  AL-335

• UNSPSC:

  12352005

• Target:

  DNA/RNA Synthesis; HCV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/adafosbuvir.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C[C@@]1([C@H](N(C=CC2=O)C(N2)=O)O[C@@](COP(OC3=CC=CC=C3)(N[C@@H](C)C(OC(C)C)=O)=O)(F)[C@H]1O)O

• Molecular Formula:

  C22H29FN3O10P

• Molecular Weight:

  545.45

• References & Citations:

  [1]Tetsuo Takehara, et al. JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study. J Gastroenterol. 2020 Jun;55 (6) :640-652.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  [1613589-09-5]